|
|
- 2018
Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetineDOI: 10.1016/j.trci.2018.04.005 Keywords: Alzheimer's disease, Cerebral amyloidosis, Neocortex, Monoamine, Serotonin, Selective serotonin reuptake inhibitor, SERT occupancy, [3H]DASB, Autoradiography, Transgenic mouse model, 5,7-dihydroxytryptamine, Stereology Abstract: Treatment with selective serotonin reuptake inhibitors has been suggested to mitigate amyloid-β (Aβ) pathology in Alzheimer's disease, in addition to an antidepressant mechanism of action
|
